Protective Life Insurance Fit Review for Kidney Disease

Research Snapshot

Why Protective Qualified for This Study

Questions This Section Answers

• Is Protective a good choice for Life Insurance for Kidney Disease compared with other carriers?
• How many AI platforms named Protective for kidney disease life insurance, and how highly did it rank?

Protective qualified because it was named by five of the seven platforms during ranking discovery and placed near the top of most lists. Its average listed rank was 2.6, with grok and perplexity each placing it first and kimi placing it second ^[1]. Only deepseek and google did not name it in the ranking stage, though both still produced full fit assessments of the company.

The qualification rests on independent recognition rather than a Protective-specific kidney-disease product. Policygenius names Protective as one of the best term life insurance options for people with chronic kidney disease ^[3], and a separate Policygenius review cited by multiple platforms identifies Protective as competitive for Stages 1–3 kidney disease ^[1]. Protective itself does not market a kidney-disease-specific policy; its public materials describe individually underwritten term and permanent life insurance with state availability and policy series requiring a quote ^[4].

This review evaluates Protective only for the Life Insurance for Kidney Disease use case. It is not a general company review, and the broader carrier set is covered in the Life Insurance for Kidney Disease consensus index.

The Product, Model, Plan, or Service Most Relevant to Life Insurance for Kidney Disease

Questions This Section Answers

• Which Protective plan should a buyer with Stage 1–3a chronic kidney disease apply for?
• Does Protective Classic Choice Term require a medical exam for a kidney disease applicant?

The most relevant Protective product for this use case is Protective Classic Choice Term life insurance, evaluated through traditional or fully underwritten application. The consumer quote flow identifies Classic Choice Term, form ICC16-TL21/TL-21, as the quoted product, with final eligibility and pricing determined after underwriting ^[5]. Protective Classic Choice Term is publicly described as offering 10-, 15-, 20-, 25-, 30-, 35-, and 40-year terms, with consumer materials stating coverage amounts from $100,000 to $50,000,000 ^[6]. One product guide states a minimum face amount of $100,000 with no set maximum, subject to underwriting ^[8].

Kidney disease is not a routine approval path. Protective's accelerated underwriting eligibility checklist lists kidney disease or a kidney disorder among conditions that can make an applicant ineligible for accelerated underwriting ^[9]. Independent underwriting guides likewise note that chronic kidney disease is excluded from accelerated and rapid eUnderwriting programs ^[10]. The practical consequence is that a kidney disease applicant should expect traditional underwriting, which Protective describes as involving possible medical examination, medical-records ordering, and additional information for complex cases ^[11].

Protective also markets universal life products with lifetime coverage when required premiums are maintained and potential cash value ^[13], and Classic Choice Term includes a Conversion Choice rider with ExtendCare that can support conversion to a permanent solution without additional underwriting or medical exams ^[14]. The public materials do not establish kidney-disease-specific approval criteria, premiums, or guarantees for any particular permanent policy ^[13].

What the AI Platforms Agreed About

Questions This Section Answers

• What did the AI platforms agree on about Protective for kidney disease life insurance?
• Is Protective considered a top carrier for Stage 1–3 chronic kidney disease?

The platforms agreed on four points. First, Protective is a legitimate contender for early-stage chronic kidney disease. Independent sources identify Stage 1–2 CKD as qualifying for standard or mildly substandard rates, while Stage 3 typically results in table ratings ^[15]. Google's assessment states Protective is recognized for its strategy to focus on table-rating kidney disease, with expected ratings between Table 4 and 10 ^[18].

Second, kidney disease pushes applicants off the fast underwriting path. Protective's own checklist and independent underwriting guides both exclude CKD from accelerated programs ^[19].

Third, Protective's financial strength is not in dispute. It holds A+ (Superior) from AM Best, AA− from S&P, AA− from Fitch, and A1 from Moody's ^[21]. Financial strength matters more than usual here because progressive kidney disease raises the eventual claim probability.

Fourth, the conversion privilege is a genuine feature for this buyer. All Protective term policies include conversion rights allowing conversion to permanent coverage without a new medical exam ^[23], and independent sources recommend permanent insurance for CKD applicants to lock in rates at today's rates ^[25]. For a progressive condition, that protects future insurability.

Where the AI Platforms Disagreed or Were Uncertain

Questions This Section Answers

• Do the AI platforms disagree about whether Protective is a good fit for kidney disease?
• Is Protective's kidney disease underwriting criteria publicly documented?

Fit ratings split three ways. Google, grok, and kimi rated Protective a "good" fit; anthropic, deepseek, openai, and perplexity rated it "mixed." The disagreement is not about facts so much as about how much weight to give unpublished underwriting criteria.

The central uncertainty is that no platform found a public Protective renal underwriting table. Public Protective materials reviewed do not state whether Stage 1, Stage 2, Stage 3a, hypertensive nephropathy, dialysis history, transplant history, or particular eGFR or creatinine ranges receive standard, rated, postponed, or declined offers ^[26]. Deepseek reported that no public Protective source confirms an explicit Stage 1–3a CKD with controlled hypertensive nephropathy underwriting program, and that this claim from the ranking stage could not be verified ^[28].

Platforms also conflicted on simplified issue. Anthropic reported that Protective Series Passport Simplified Issue Term covers up to $250,000 with no medical exam for ages 18–50, and Simplified Issue Whole Life covers up to $100,000 with no exam up to age 65 ^[29]. Kimi, by contrast, reported that Protective has limited no-medical-exam policy options ^[32]. Both can be true if the simplified products exist but are narrow; the simplified issue health questions are not publicly disclosed, so kidney disease approval likelihood under simplified underwriting is unconfirmed ^[31].

Two further conflicts are worth flagging. Protective's use of NT-ProBNP cardiovascular screening and stricter family history guidelines may disadvantage CKD applicants with comorbidities, but the magnitude is unclear ^[33]. And one Policygenius review cited by grok and kimi dates to 2023–2024, so 2026 outcomes may differ ^[35].

Use-Case-Specific Features and Capabilities

Questions This Section Answers

• What features does Protective Classic Choice Term offer a kidney disease applicant?
• Can a Protective term policy be converted to permanent coverage if kidney function declines?

Protective's relevant capabilities for this use case are term length, coverage amount, conversion, and full underwriting depth. Classic Choice Term offers 10- to 40-year term periods ^[37], which is among the longest available and useful for younger CKD applicants seeking extended coverage ^[39]. Coverage amounts are publicly stated from $100,000 to $50,000,000, subject to state variation and underwriting ^[37].

Traditional underwriting is the mechanism that makes Protective structurally appropriate for kidney disease. Protective describes traditional underwriting as involving possible medical examination, medical-records ordering, and additional information for complex cases or detailed health profiles ^[40]. Independent sources note that insurers assess severity using GFR levels, creatinine results, and the presence of protein in the urine, and that insurers request an attending physician statement from the treating physician for all kidney disease applications ^[42]. Protective's application process may include health and lifestyle questions, medical examination, blood and urine samples, and application review ^[41].

The conversion privilege is the most use-case-specific advantage. Protective states that many Classic Choice term policies can be converted to permanent coverage without a new medical exam, though conversion options vary by term length and product availability and the new policy's pricing may change ^[45]. The Conversion Choice rider with ExtendCare can support conversion to a permanent solution without additional underwriting or medical exams ^[46]. Independent sources describe convertible term as an excellent option for people who have developed health problems because they automatically qualify without medical questions ^[47].

Protective's marketing also states that diabetic applicants can qualify for standard rates versus substandard at many companies, and that hypertension with average readings of no more than 135/85 qualifies for the best rates ^[48]. Those are company-reported positioning claims, not verified outcomes for kidney disease applicants.

Pricing, Fees, Contracts, and Ongoing Costs

Questions This Section Answers

• How much does Protective cost per month for a kidney disease applicant, and are there setup or cancellation fees?
• What table rating and premium increase should a Stage 3 CKD applicant expect from Protective?

No platform found published Protective pricing for kidney disease applicants. Pricing is quote-based and depends on age, state, coverage amount, term length, tobacco status, health disclosures, examination results, medical records, and final underwriting class ^[50]. The public sample premium of $25 per month is for a healthy 30-year-old hypothetical applicant and should not be treated as a CKD price ^[50].

Industry benchmarks give a rough frame. Fair-rated kidney disease policies average $58 per month for women and $72 per month for men at age 40 ^[51]. One platform reported that a 50-year-old non-smoking male with minimal kidney impact could pay less than $103 per month for $500,000 of 20-year term, and a female about $78 per month, positioned as more affordable than competitors for the same profile ^[52]. That figure is platform-reported and not confirmed by Protective.

Table ratings are the expected mechanism. Google's assessment states premiums are typically issued with table ratings between Table 4 and Table 10, which add a percentage surcharge usually around 25% per table, resulting in roughly a 100% to 250% increase over the standard base rate ^[53]. Independent sources confirm Stage 3 usually results in a table rating with higher premiums ^[54]. The spread between the most and least favorable carrier for the same diagnosis often exceeds 50%, which is why a pre-assessment matters before committing ^[56].

On contract terms: term premiums are generally level during the applicable guaranteed-premium period, and Protective states premiums increase after the initial guaranteed period in the quote disclosure ^[50]. Coverage requires timely premium payments and is subject to grace-period, lapse, contestability, and suicide-period provisions ^[50]. Classic Choice term has no cash value ^[50]. Conversion availability, deadlines, eligible permanent products, and pricing must be verified in the issued policy ^[50]. No kidney-disease-specific fee was publicly identified, and potential costs associated with required medical examination or records are unclear from the reviewed public materials ^[50]. Simplified issue policies from Protective cost more than fully underwritten alternatives because underwriters have less health information ^[58].

Best Suited For

Questions This Section Answers

• Who is Protective best suited for among kidney disease life insurance buyers?
• Is Protective a good choice for a younger applicant with early-stage CKD who wants long term coverage?

Protective is best suited to applicants with stable, well-documented, early-stage kidney impairment who are willing to complete full medical underwriting. Independent sources indicate Stage 1–2 CKD often qualifies for traditional coverage with manageable ratings, while carefully selected Stage 3a cases may also access traditional policies ^[59]. One platform specifically notes Protective is reasonable on controlled hypertensive nephropathy, making it suitable for CKD stemming from well-managed high blood pressure ^[60].

It also suits buyers who want level-premium term coverage over a long horizon. Term lengths run to 40 years ^[61], and independent sources describe Protective as competitive for Stages 1–3 kidney disease with long term options ^[63].

It suits buyers who value a possible conversion to permanent coverage without new medical underwriting, subject to policy terms ^[65]. Independent sources recommend permanent insurance for CKD applicants to lock in rates at today's rates, recognizing that future insurability may become harder if kidney function declines ^[67].

Finally, it suits buyers who want a financially strong insurer. Protective holds A+ (Superior) from AM Best, AA− from S&P, AA− from Fitch, and A1 from Moody's ^[68].

Probably Not Best Suited For

Questions This Section Answers

• Who should not choose Protective for Life Insurance for Kidney Disease?
• Is Protective suitable for a dialysis patient or someone with Stage 4–5 CKD?

Protective is probably not the right choice for applicants on dialysis or with advanced kidney disease. Protective lists kidney dialysis as an uninsurable risk, meaning individuals requiring dialysis face automatic decline for fully underwritten and simplified issue policies ^[70]. Independent sources confirm dialysis applicants are usually limited to guaranteed issue policies ^[71], and that applicants on dialysis or with advanced CKD are generally declined for fully underwritten term ^[73].

It is also a poor fit for buyers who want simplified issue or rapid approval based on limited health information. Kidney disease or a kidney disorder can make an applicant ineligible for Protective's accelerated underwriting path ^[74], and CKD is excluded from accelerated and rapid eUnderwriting programs ^[75].

Buyers who need guaranteed-issue coverage with no health questions should look elsewhere. Protective explains that guaranteed-issue life insurance generally has smaller death benefits and higher-than-normal premiums, and distinguishes it from medically underwritten coverage ^[76]. The reviewed Protective materials do not show that a guaranteed-issue Protective policy is the appropriate product for this buyer ^[76].

New York residents are excluded. The consumer quote page states Classic Choice is not available in New York ^[77], and one platform reports Protective life insurance is not available in New York at all ^[78]. Applicants with polycystic kidney disease and impaired renal function are typically declined, though those with preserved renal function may qualify for a higher table rating ^[79]. One platform also reports Protective is not a strong fit for marijuana users, recent bankruptcy filers, or visa holders ^[78].

When Another Option May Be Better

Questions This Section Answers

• What is a better alternative to Protective for a buyer with Stage 4–5 CKD or on dialysis?
• When should a kidney disease buyer choose a different carrier instead of Protective?

Another option may be better in five situations. If the applicant has Stage 4–5 CKD or is on dialysis, guaranteed issue whole life from competitors such as Mutual of Omaha, USAA, or Transamerica offers coverage with graded benefits and no health questions ^[80]. If the applicant needs coverage exceeding $250,000 without a medical exam, other carriers offer up to $2–3 million simplified issue coverage ^[82].

If the applicant is age 50 or older seeking simplified issue without an exam, Protective limits simplified issue term to ages 18–50, while competitors extend age limits to 65–80 ^[83]. If the applicant prioritizes kidney disease specialization, Corebridge Financial is specifically noted for CKD affordability and underwriting flexibility in independent reviews ^[85]. If the applicant has uncontrolled comorbidities such as diabetes or hypertension, carriers with more lenient underwriting for multiple conditions may offer better rates than Protective's stricter cardiovascular screening ^[87].

A specialty independent broker can compare several insurers with published or broker-accessible renal underwriting guidelines, and another carrier may confirm standard or mildly rated treatment for the buyer's exact eGFR, diagnosis, cause, treatment history, and comorbidities ^[89]. Because impaired-risk spread between carriers often exceeds 50%, a pre-assessment before committing is the practical recommendation ^[90]. Buyers who want to compare the full carrier set can start with the life insurance category directory.

Questions to Verify Before Buying

Questions This Section Answers

• What should a buyer confirm with Protective before signing a kidney disease life insurance contract?
• Which lab values and medical records will Protective require for a CKD application?

For the buyer's exact CKD stage, eGFR trend, creatinine, proteinuria or albuminuria, diagnosis cause, treatment, and physician records, will Protective consider standard, rated, postponed, or declined coverage ^[92]? Will kidney disease require traditional underwriting rather than accelerated underwriting ^[93]? Which laboratory tests, medical records, nephrologist statements, or attending-physician reports are required, and who pays any examination-related costs ^[92]?

What premium and rating class apply for the requested face amount and term, including tobacco and comorbidity adjustments ^[92]? Is Protective Classic Choice term available in the buyer's state and for the requested age, face amount, and term ^[92]? What are the exact conversion deadline, eligible permanent products, conversion limits, and pricing rules ^[92]?

Are there exclusions, contestability provisions, suicide-period provisions, or state-specific amendments that affect the intended coverage ^[92]? Would applying through an independent broker produce a materially better renal underwriting result from another carrier ^[92]? If the application is postponed or declined, will Protective provide the reason and can the application be withdrawn before adverse underwriting information is shared where applicable ^[92]? For permanent coverage, what guaranteed premium schedule, lapse risks, charges, cash-value assumptions, and illustration guarantees apply ^[92]?

Final AI Consensus Verdict

Protective is a mixed fit for Life Insurance for Kidney Disease. Five of seven platforms named it in the ranking stage, with an average listed rank of 2.6 and a best rank of 1, and three platforms rated the fit "good" while four rated it "mixed." The case for Protective rests on independent recognition as a competitive carrier for Stages 1–3 kidney disease, long term lengths up to 40 years, a conversion privilege that protects future insurability without a new medical exam, and top-tier financial strength. The case against rests on the absence of any published renal underwriting table, exclusion from accelerated underwriting, no guaranteed-issue product for advanced CKD, low simplified issue limits, and stricter cardiovascular and family history screening that may disadvantage applicants with comorbidities.

The practical conclusion is that Protective is worth a fully underwritten quote for stable, mild CKD, particularly when term coverage and future conversion are priorities, but it is not a clearly superior choice on public information. A multi-carrier comparison through an independent broker is advisable before purchase. AI-platform agreement on this point reflects shared source material, not verified product quality or approval outcomes.

How This Review Was Produced

This review was produced from seven platform fit-research responses collected for the Life Insurance for Kidney Disease use case, each evaluating Protective against the same buyer profile: a U.S. consumer with chronic kidney disease or a history of impaired kidney function seeking life insurance. The ranking stage counted how many platforms named Protective during discovery; the fit stage captured each platform's product identification, strengths, limitations, pricing notes, and verification questions. Platform outputs were compared for agreement and conflict, and every factual claim was mapped to a supplied citation ID. No independent testing, customer interviews, or carrier confirmation was performed.

Methodology Limitations

Several limitations apply. Platform-reported research dates differ from the authoritative run date of 2026-09-22; deepseek reported a research date of 2026-01-15, and its search was disabled, so its claims are model-reported rather than retrieved. Platform-reported dates are provenance metadata and do not independently prove freshness.

Citations are platform-reported evidence, not independently verified facts. The supplied URLs were collected from platform responses and were not independently validated by the writer stage. No independent evidence was located confirming Protective's approval rates, average CKD premiums, or customer outcomes for kidney-disease applicants ^[95]. Protective's public materials describe multiple underwriting paths, but the likely path for a specific applicant is unclear until application data are reviewed ^[96].

Conflicting product names and capabilities were not resolved by guessing. The simplified issue conflict between anthropic and kimi is described rather than settled. One Policygenius review cited by grok and kimi dates to 2023–2024, so 2026 outcomes may vary ^[98]. Protective's terms of use state that Protective makes no representation as to the financial or other suitability of any product described on its site and that users should contact a competent financial advisor to evaluate suitability (official:C3).